View
3
Download
0
Category
Preview:
Citation preview
2
3
4
5
FEB
JAN
MAR
6
7
8
9
Increased exports to Japan & other API proportion increased
10
4.6% 28.8%
3.5% 133.1%
11.5% 157.1%
11.5% 139.7%
5.9% 25.9%
4.8% 126.2%
12.9% 149.3%
12.9% 132.9%
11
18.4% -0.7%
TTB -63.1%
TTB -82.3%
TTB -88.0%
12
9.3% 3.9%
26.5% 4.7%
17.2% 3.5%
26.6% 26.3%
-1.2% 4.3%
35.3% -64.1%
-6.0% -8.9%
4.8% 21.5%
13
14
789.3
15
16
17
Diabetes/Obesity
Rare diseases
Cancer
Autoimmune diseases
Others
B Beijing Hanmi
Pre-Clinical Phase 2 Phase 3Phase 1
LAPSInsulin ComboHM14220Diabetes
SANOFI
GBM Stem Cell TherapyHM21001Glioblastoma
AJOU Univ
LAPSTriple AgonistHM15211NASH
LAPSGCG AnalogHM15136Obesity
LAPSGCG AnalogHM15136Congenital Hyperinsulinism
PD-1/CD47BH29XXTargeted Immuno-oncology
B
LAPSASBHM15450Mucopolysaccharidosis
LAPSGLP/GCGHM12525A·JNJ64565111Obesity/Diabetes
JANSSEN
LAPSIns/LAPSInsulin AnalogHM12460A/HM12470Diabetes
Pan-RAF InhibitorBelvarafenibSolid tumors
GENENTECH
PD-1/PD-L1BH2996HTargeted Immuno-oncology
B
EfpeglenatideLAPSExd4 AnalogObesity/Diabetes
SANOFI
EfpegsomatropinLAPShGHGH deficiency
Luminate®
Integrin inhibitor
DMEALLEGRO
BTK InhibitorHM71224Autoimmune disease
Pan-HER InhibitorPoziotinibSolid tumor
SPECTRUM
Rolontis™EflapegrastimNeutropenia
SPECTRUM
Oraxol™Paclitaxel+HM30181ASolid tumor
ATHENEX
PD-1/HER2BH2950Targeted Immuno-oncology
B
INNOVENT
FLT3 InhibitorHM43239
AML
TNF-α/IL-17BH1657Targeted Autoimmune diseases
B
LAPSGLP-2 AnalogHM15912Short Bowel Syndrome
LAPSInsulin148HM12480Diabetes
LAPSGCG ComboHM14320Obesity/Diabetes/NASH
Luminate®
Integrin inhibitorRetinitis Pigmentosa
Oratecan™Irinotecan+HM30181ASolid tumor
Oradoxel™Docetaxel+HM30181ASolid tumor
ATHENEX
ATHENEX
A2AR antagonist
Solid tumor
LSD1 Inhibitor
SCLC, AML
18
Recommended